ENLIVEX THERAPEUTICS LTD ENLV 深 沪
等待开盘 12-16 09:30:00 美东时间
0.861
-0.068
-7.31%
华盛通- 最 高0.9587
- 今 开0.9576
- 成交量 112.76万股
- 最 低 0.85
- 昨 收 0.9289
- 总市值 2054.20万
- 52周最高 2.10
- 市盈率 静 --
- 换手率 4.73%
- 52周最低 0.8313
- 委 比 35.06%
- 总股本 2385.83万
- 历史最高 44.90
- 量 比 1.09
- 振 幅 11.70%
- 历史最低 0.8101
- 每 手 1
- 风险率 0.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
Enlivex Therapeutics will host a virtual fireside chat on December 11, 2025, at 11:00 am ET. Shai Novik, the company's Executive Chairman, will discuss updates following the recent $212 million private placement, including the launch of a digital asset treasury strategy focused on RAIN token accumulation and the advancement of Allocetra's clinical development for treating osteoarthritis. The event will include a Q&A session, and a recording will ...
12-04 13:00
Enlivex Completes $212 Million Private Placement, Expands Digital Asset Strategy
Enlivex ( ($ENLV) ) just unveiled an announcement. On November 24, 2025, Enlive...
11-26 21:28
3 Penny Stocks to Watch Now, 11/25/25
Antelope Enterprise Holdings, Enlivex Therapeutics, and Inno Holdings are the 3...
11-25 23:13
D. Boral Capital Downgrades Enlivex Therapeutics to Hold
D. Boral Capital analyst Jason Kolbert downgrades Enlivex Therapeutics (NASDAQ:ENLV) from Buy to Hold.
11-24 23:41
Enlivex Therapeutics Ltd. Announces Six-Month Efficacy Data From Phase IIa Allocetra Trial in Knee Osteoarthritis Patients Aged 60+
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive six-month efficacy data from the Phase IIa stage of its randomized,
11-24 19:43
Enlivex Reschedules Annual Meeting Due to Lack of Quorum
An update from Enlivex ( ($ENLV) ) is now available. On November 10, 2025, Enli...
11-11 06:28
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Enlivex Therapeutics To Present Late-breaking Poster At ACR Convergence 2025 Featuring Phase IIa Topline Data For Allocetra In Patients With Moderate-To-Severe Knee Osteoarthritis. Data Showed Clinically Meaningful And Statistically Significant Improvements In Pain Reduction And Function Versus Placebo
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of
10-28 20:19
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
Enlivex Therapeutics will present late-breaking Phase IIa clinical data for Allocetra™ in knee osteoarthritis at ACR Convergence 2025. The data show statistically significant improvement in pain and function in idiopathic age-related osteoarthritis patients. Professor Philip Conaghan will present the findings, including new biomarker data, on October 28. Enlivex is developing Allocetra™, an immunotherapy that reprograms macrophages, targeting lif...
10-28 12:15
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Enlivex Therapeutics will participate in a webinar on September 30, 2025, discussing breakthroughs in knee osteoarthritis treatment. The webinar, hosted by D. Boral Capital, will feature leading experts and discuss positive Phase IIa data from Enlivex's Allocetra™ program, showing significant pain reduction and functional improvement in patients.
09-29 12:15
